Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-002805
Filing Date
2023-02-14
Accepted
2023-02-14 17:02:32
Documents
63
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q ktra-20221231.htm   iXBRL 10-Q 2410960
2 EX-31.1 ktra-ex31_1.htm EX-31 21006
3 EX-31.2 ktra-ex31_2.htm EX-31 20712
4 EX-32.1 ktra-ex32_1.htm EX-32 12240
5 EX-32.2 ktra-ex32_2.htm EX-32 12240
6 GRAPHIC img138768146_0.jpg GRAPHIC 108936
7 GRAPHIC img138768146_1.jpg GRAPHIC 40295
  Complete submission text file 0000950170-23-002805.txt   8521435

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ktra-20221231_cal.xml EX-101.CAL 22038
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ktra-20221231_pre.xml EX-101.PRE 386020
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ktra-20221231.xsd EX-101.SCH 71514
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ktra-20221231_def.xml EX-101.DEF 287364
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ktra-20221231_lab.xml EX-101.LAB 481170
57 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20221231_htm.xml XML 1366295
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

EIN.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-37823 | Film No.: 23631239
SIC: 2834 Pharmaceutical Preparations